Last reviewed · How we verify
Beijing Tide Pharmaceutical Co., Ltd — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
2 Phase 2
5 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| TDI01 suspension | TDI01 suspension | phase 3 | ACE inhibitor | ACE | Cardiovascular |
Therapeutic area mix
- Cardiovascular · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
- Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
- Ain Shams University · 1 shared drug class
- Bioprojet · 1 shared drug class
- Boryung Pharmaceutical Co., Ltd · 1 shared drug class
- Children's Hospital of Fudan University · 1 shared drug class
- Daewon Pharmaceutical Co., Ltd. · 1 shared drug class
- Ace Cells Lab Limited · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Beijing Tide Pharmaceutical Co., Ltd:
- Beijing Tide Pharmaceutical Co., Ltd pipeline updates — RSS
- Beijing Tide Pharmaceutical Co., Ltd pipeline updates — Atom
- Beijing Tide Pharmaceutical Co., Ltd pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Beijing Tide Pharmaceutical Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/beijing-tide-pharmaceutical-co-ltd. Accessed 2026-05-16.